Viral hepatitis and hepatocellular carcinoma

World Journal of Surgical Oncology

Volumn 3, Issue , 2005, Pages

  Michielsen, Peter P ^a   Francque, Sven M ^a   van Dongen, Jurgen L ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS VACCINE; PEGINTERFERON; RIBAVIRIN; VIRUS PROTEIN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; CHRONIC DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; GENE MUTATION; GENOME ANALYSIS; GEOGRAPHIC DISTRIBUTION; HEPATITIS A; HEPATITIS B; HUMAN; INFLAMMATION; INFORMATION PROCESSING; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATHOGENESIS; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; VIRUS HEPATITIS;

EID: 27444440889     PISSN: 14777819     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-3-27     Document Type: Review

References (211)

1. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001, 35:421-430.
2. Llovet JM, Beaugrand M: Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003, 38(Suppl 1):136-149.
3. Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271-285.
4. Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R: Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985, 1:1357-1360.
5. Poynard T, Aubert A, Lazizi Y, Bedossa P, Hamelin B, Terris B, Naveau S, Dubreuil P, Pillot J, Chaput JC: Independent risk factors for hepatocellular carcinoma in French drinkers. Hepatology 1991, 13:896-901.
6. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 325:675-680.
7. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328:1797-1801.
8. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C: A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999, 31:133-141.
9. International Agency for Research on Cancer: Hepatitis Viruses. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 59. Lyon: IARC; 1994.
10. Kew MC, Dusheiko GM, Hadziyannis SJ, Paterson A: Does Delta infection play a part in the pathogenesis of hepatitis B virus related hepatocellular carcinoma? Br Med J 1984, 288:1727.
11. Verme G, Brunetto MR, Oliveri F, Baldi M, Forzani B, Piantino P, Ponzetto A, Bonino F: Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci 1991, 36:1134-1136.
12. EASL Jury: EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003, 38:533-540.
13. Yotsuyanagi H, Yasuda K, Iino S, Moriya K, Shintani Y, Fujie H, Tsutsumi T, Kimura S, Koike K: Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998, 27:1377-1382.
14. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y: e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976, 294:746-749.
15. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ, Pao CC: Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986, 90:263-267.
16. Beasley RP, Hwang LY, Lin CC, Chien CS: Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet 1981, 2:1129-1133.
17. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, Alter HJ: Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990, 12:671-675.
18. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, Christensen E, Giustina G, Noventa F: Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994, 21:656-666.
19. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, Krogsgaard K, Degos F, Carneiro De Moura M, Solinas A, Noventa F, Realdi G: Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology 1995, 21:77-82.
20. Fattovich G: Progression of hepatitis B and C to hepatocellular carcinoma in western countries. Hepatogastroenterology 1998, 45:1206-1213.
21. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E: Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002, 97:2886-2895.
22. Sakuma K, Saitoh N, Kasai M, Jitsukawa H, Yoshino I, Yamaguchi M, Nobutomo K, Yamumi M, Tsuda F, Komazawa T: Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology 1988, 8:1642-1646.
23. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ, Taiwan Community-Based Cancer Screening Project Group: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347:168-174.
24. Ohkubo K, Kato Y, Ichikawa T, Kajiya Y, Takeda Y, Higashi S, Hamasaki K, Nakao K, Nakata K, Eguchi K: Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002, 94:2663-2668.
25. Yano Y, Yamashita F, Sumie S, Ando E, Fukumori K, Kiyama M, Oyama T, Kuroki S, Kato O, Yamamoto H, Tanaka M, Sata M: Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. Am J Gastroenterol 2002, 97:156-161.
26. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M: Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988, 69:2575-2583.
27. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R: A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000, 81:67-74.
28. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO: Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002, 83:2059-2073.
29. Norder H, Courouce AM, Magnius LO: Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994, 198:489-503.
30. Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000, 118:554-559.
31. Ding X, Mizokami M, Yao G, Xu B, Orito E, Ueda R, Nakanishi M: Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. Intervirology 2001, 44:43-47.
32. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M: Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001, 34:590-594.
33. Chen JD, Liu CJ, Lee PH, Chen PJ, Lai MY, Kao JH, Chen DS: Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2004, 2:64-71.
34. Kao JH, Chen PJ, Lai MY, Chen DS: Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003, 124:327-334.
35. Sugauchi F, Ohno T, Orito E, Sakugawa H, Ichida T, Komatsu M, Kuramitsu T, Ueda R, Miyakawa Y, Mizokami M: Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol 2003, 70:537-544.
36. Anon: Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999, 6:35-47.
37. Crowe J, Doyle C, Fielding JF, Holloway H, Keegan M, Kelleher D, Kelly P, Leader M, Little M, McDonald G, McCarthy CF, McWeeney J, O'Keane C, Rajan E: Presentation of hepatitis C in a unique uniform cohort 17 years from inoculation [abstract]. Gastroenterology 1995, 108:1054.
38. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997, 349:825-832.
39. Hopf U, Moller B, Kuther D, Stemerowicz R, Lobeck H, Ludtke-Handjery A, Walter E, Blum HE, Roggendorf M, Deinhardt F: Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990, 10:69-76.
40. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ: Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991, 14:969-974.
41. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G: Long-term follow-up of non-A, non-B (type C) posttransfusion hepatitis. J Hepatol 1992, 6:273-281.
42. Koretz RL, Abbey H, Coleman E, Gitnick G: Non-A, non-B posttransfusion hepatitis. Looking back in the second decade. Ann Intern Med 1993, 119:110-115.
43. Mattsson L, Sonnerborg A, Weiland O: Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993, 13:274-278.
44. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001, 48:251-259.
45. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, Mondelli MU: Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997, 25:754-758.
46. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993, 18:47-53.
47. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S: Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000, 47:131-136.
48. Kiyosawa K, Tanaka E, Sodeyama T: Hepatitis C virus and hepatocellular carcinoma. Curr Stud Hematol Blood Transfus 1998, 62:161-180.
49. Tong MJ, El Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995, 332:1463-1466.
50. Pozzato G, Kaneko S, Moretti M, Croce LS, Franzin F, Unoura M, Bercich L, Tiribelli C, Crovatto M, Santini G, Kobayashi S, Crovatto M, Santini G, Kobayashi S: Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994, 43:291-296.
51. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, Mondelli MU: Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997, 25:754-758.
52. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A: Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997, 25:211-215.
53. Romeo R, Rumi MG, Del Ninno E, Colombo M: Hepatitis C virus genotype 1b and risk of hepatocellular carcinoma. Hepatology 1997, 26:1077.
54. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, Tran van Nhieu J, Seigneurin JM, Buffet C, Dhumeaux D: Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998, 28:27-33.
55. Sato S, Fujiyama S, Tanaka M, Yamasaki K, Kuramoto I, Kawano S, Sato T, Mizuno K, Nonaka S: Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 1994, 21:159-166.
56. Donato F, Boffetta P, Puoti M: A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998, 75:347-354.
57. Chiba T, Matsuzaki Y, Abei M, Shoda J, Tanaka N, Osuga T, Aikawa T: The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol 1996, 91:1195-1203.
58. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, Shuto T, Yamamoto T, Ikebe T, Kinoshita H: Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 1999, 86:793-798.
59. Marusawa H, Osaki Y, Kimura T, Ito K, Yamashita Y, Eguchi T, Kudo M, Yamamoto Y, Kojima H, Seno H, Moriyasu F, Chiba T: High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut 1999, 45:284-288.
60. Kao JH, Chen PJ, Lai MY, Chen DS: Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002, 40:4068-4071.
61. Kurtz RC: Hepatocellular carcinoma and coinfection with hepatitis B and C. Making a difficult situation worse. Cancer 1999, 86:741-743.
62. Anon: National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997, 26(Suppl 1):2S-10S.
63. Chlabicz S, Grzeszczuk A: Hepatitis B virus vaccine for patients with hepatitis C virus infection. Infection 2000, 28:341-345.
64. Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V, Soriano V: Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001, 96:179-183.
65. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C: The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994, 87:555-561.
66. Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, Beasley RP, Hwang LY: The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol 2001, 33:123-126.
67. Ohnishi K, Iida S, Iwama S, Goto N, Nomura F, Takashi M, Mishima A, Kono K, Kimura K, Musha H, Kotota K, Okuda K: The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface antigen carriage. Cancer 1982, 49:672-677.
68. Qiao ZK, Halliday ML, Rankin JG, Coates RA: Relationship between hepatitis B surface antigen prevalence, per capita alcohol consumption and primary liver cancer death rate in 30 countries. J Clin Epidemiol 1988, 41:787-792.
69. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G: Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002, 155:323-331.
70. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxi A, Ciccaglione A, Giuseppetti R, Stroffolini T, Pagliaro L: Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992, 116:97-102.
71. Trichopoulos D, Day NE, Kaklamani E, Tzonou A, Munoz N, Zavitsanos X, Koumantaki Y, Trichopoulou A: Hepatitis B virus, tobacco smoking and ethanol consumption in the etiology of hepatocellular carcinoma. Int J Cancer 1987, 39:45-49.
72. Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fasola M, Gelatti U, Portera G, Boffetta P, Nardi G: Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Hepatology 1997, 26:579-584.
73. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ: Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002, 36:1206-1213.
74. Chen DS, Kuo G, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, Hsu HM, Chang MH, Chen CJ, Hahn LC, Choo QL, Wang TH, Houghton M: Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990, 162:817-822.
75. Chuang WL, Chang WY, Lu SN, Su WP, Lin ZY, Chen SC, Hsieh MY, Wang LY, You SL, Chen CJ: The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer 1992, 69:2052-2054.
76. Lee SD, Lee FY, Wu JC, Hwang SJ, Wang SS, Lo KJ: The prevalence of anti-hepatitis C virus among Chinese patients with hepatocellular carcinoma. Cancer 1992, 69:342-345.
77. Jeng JE, Tsai JF: Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan. J Med Virol 1991, 34:74-77.
78. Leung NW, Tam JS, Lai JY, Leung TW, Lau WY, Shiu W, Li AK: Does hepatitis C virus infection contribute to hepatocellular carcinoma in Hong Kong? Cancer 1992, 70:40-44.
79. Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Suzuki H, Tsuji T, Yano M, Kuo G, Choo QL, Houghton M, Oda T: A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991, 67:429-433.
80. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, Choo QL, Houghton M, Kuo G: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990, 87:6547-6549.
81. Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, Beasley RP, Hwang LY: The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol 2001, 33:123-126.
82. Kew MC, Houghton M, Choo QL, Kuo G: Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 1990, 335:873-874.
83. Yu MC, Tong MJ, Coursaget P, Ross RK, Govindarajan S, Henderson BE: Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst 1990, 82:1038-1041.
84. Di Di Bisceglie AM, Order SE, Klein JL, Waggoner JG, Sjogren MH, Kuo G, Houghton M, Choo QL, Hoofnagle JH: The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991, 86:335-338.
85. Hadziyannis S, Tabor E, Kaklamani E, Tzonou A, Stuver S, Tassopoulos N, Mueller N, Trichopoulos D: A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma. Int J Cancer 1995, 60:627-631.
86. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, Dioguardi N, Houghton M: Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989, 2:1006-1008.
87. Levrero M, Tagger A, Balsano C, De Marzio E, Avantaggiati ML, Natoli G, Diop D, Villa E, Diodati G, Alberti A: Antibodies to hepatitis C virus in patients with hepatocellular carcinoma. J Hepatol 1991, 12:60-63.
88. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxi A, Ciccaglione A, Giuseppetti R, Stroffolini T, Pagliaro L: Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann Intern Med 1992, 116:97-102.
89. Stroffolini T, Andreone P, Andriulli A, Ascione A, Craxi A, Chiaramonte M, Galante D, Manghisi OG, Mazzanti R, Medaglia C, Pilleri G, Rapaccini GL, Simonetti RG, Taliani G, Tosti ME, Villa E, Gasbarrini G: Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998, 29:944-952.
90. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, Ventura M, Vall M, Bruguera M, Bru C, Castillo R, Rodes J: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989, 2:1004-1006.
91. Nalpas B, Driss F, Pol S, Hamelin B, Housset C, Brechot C, Berthelot P: Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol 1991, 12:70-74.
92. Van Roey G, Fevery J, Van Steenbergen W: Hepatocellular carcinoma in Belgium: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients. Eur J Gastroenterol Hepatol 2000, 12:61-66.
93. Haydon GH, Jarvis LM, Simmonds P, Harrison DJ, Garden OJ, Hayes PC: Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population. Gut 1997, 40:128-132.
94. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE: Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res 1989, 49:2506-2509.
95. El Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750.
96. El Serag HB, Mason AC: Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000, 160:3227-3230.
97. Benhamiche AM, Faivre C, Minello A, Clinard F, Mitry E, Hillon P, Faivre J: Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. J Hepatol 1998, 29:802-806.
98. Law MG, Roberts SK, Dore GJ, Kaldor JM: Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust 2000, 173:403-405.
99. Yoshizawa H: Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002, 62(Suppl 1):8-17.
100. Kiyosawa K, Furutu S: Clinical aspects and epidemiology of hepatitis B and C viruses in hepatocellular carcinoma in Japan. Cancer Chemother Pharmacol 1992, 31(Suppl 1):150-156.
101. Deuffic S, Buffat L, Poynard T, Valleron AJ: Modeling the hepatitis C virus epidemic in France. Hepatology 1999, 29:1596-1601.
102. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS: The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000, 31:777-782.
103. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T, Alter HJ: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002, 99:15584-15589.
104. Garcia-Tsao G: Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001, 120:726-748.
105. Solmi L, Primerano AM, Gandolfi L: Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. Am J Gastroenterol 1996, 91:1189-1194.
106. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS, Bass EB: Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002, 36(Suppl 1):84-92.
107. Di Bisceglie AM, Hoofnagle JH: Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989, 64:2117-2120.
108. Izzo F, Cremona F, Ruffolo F, Palaia R, Parisi V, Curley SA: Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis. Ann Surg 1998, 227:513-518.
109. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, Hsu HC, Chuang CN, Yang PC, Wang TH, Lin JT, Lee CZ: Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985, 89:259-266.
110. Collier J, Sherman M: Screening for hepatocellular carcinoma. Hepatology 1998, 27:273-278.
111. Kim CM, Koike K, Saito I, Miyamura T, Jay G: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991, 351:317-320.
112. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4:1065-1067.
113. Summers J, Smolec JM, Snyder R: A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci USA 1978, 75:4533-4537.
114. Weinberg RA: Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989, 49:3713-3721.
115. Idilman R, De Maria N, Colantoni A, Van Thiel DH: Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepat 1998, 5:285-299.
116. Nakanuma Y, Terada T, Ueda K, Terasaki S, Nonomura A, Matsui O: Adenomatous hyperplasia of the liver as a precancerous lesion. Liver 1993, 13:1-9.
117. Theise ND: Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Semin Liver Dis 1995, 15:360-371.
118. Sh Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M, Mitamura K, Ueno Y: Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998, 351:1773-1777.
119. Sugitani S, Sakamoto M, Ichida T, Genda T, Asakura H, Hirohashi S: Hyperplastic foci reflect the risk of multicentric development of human hepatocellular carcinoma. J Hepatol 1998, 28:1045-1053.
120. Lee RG, Tsamandas AC, Demetris AJ: Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology 1997, 26:1415-1422.
121. Borzio M, Bruno S, Roncalli M, Mels GC, Ramella G, Borzio F, Leandro G, Servida E, Podda M: Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995, 108:812-817.
122. Zhao M, Zhang NX, Laissue JA, Zimmermann A: Immunohistochemical analysis of p53 protein overexpression in liver cell dysplasia and in hepatocellular carcinoma. Virchows Arch 1994, 424:613-621.
123. Kew MC: Hepatitis B and C viruses and hepatocellular carcinoma. Clin Lab Med 1996, 16:395-406.
124. Kew MC: Hepatitis viruses and hepatocellular carcinoma. Res Virol 1998, 149:257-262.
125. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL, Palmiter RD: Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989, 59:1145-1156.
126. Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J, Hofseth LJ, Kaul R, Wang XW: Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004, 39:518-527.
127. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS: Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676.
128. Delpuech O, Trabut JB, Carnot F, Feuillard J, Brechot C, Kremsdorf D: Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. Oncogene 2002, 21:2926-2937.
129. Hann HW, Lee J, Bussard A, Liu C, Jin YR, Guha K, Clayton MM, Ardlie K, Pellini MJ, Feitelson MA: Preneoplastic markers of hepatitis B-virus associated hepatocellular carcinoma. Cancer Res 2004, 64:7329-7335.
130. Chen PJ, Chen DS, Lai MY, Chang MH, Huang GT, Yang PM, Sheu JC, Lee SC, Hsu HC, Sung JL: Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology 1989, 96(2 Pt 1):527-529.
131. Lugassy C, Bernuau J, Thiers V, Krosgaard K, Degott C, Wantzin P, Schalm SW, Rueff B, Benhamou JP, Tiollais P, Bréchot C: Sequences of hepatitis B virus DNA in the serum and liver of patients with acute benign and fulminant hepatitis. J Infect Dis 1987, 155:64-71.
132. Koshy R, Maupas P, Muller R, Hofschneider PH: Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues. J Gen Virol 1981, 57(Pt 1):95-102.
133. Rowley JD: Molecular cytogenetics: Rosetta stone for understanding cancer - twenty-ninth G. H. A. Clowes memorial award lecture. Cancer Res 1990, 50:3816-3825.
134. Schimke RT: The search for early genetic events in tumorigenesis: an amplification paradigm. Cancer Cells 1990, 2:149-151.
135. Slagle BL, Zhou YZ, Butel JS: Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas. Cancer Res 1991, 51:49-54.
136. Robinson WS: Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu Rev Med 1994, 45:297-323.
137. Shirakata Y, Kawada M, Fujiki Y, Sano H, Oda M, Yaginuma K, Kobayashi M, Koike K: The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells. Jpn J Cancer Res 1989, 80:617-621.
138. Twu JS, Schloemer RH: Transcriptional trans-activating function of hepatitis B virus. J Virol 1987, 61:3448-3453.
139. Paterlini P, Poussin K, Kew M, Franco D, Brechot C: Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995, 21:313-321.
140. Henkler FF, Koshy R: Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. J Viral Hepat 1996, 3:109-121.
141. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC: Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994, 91:2230-2234.
142. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA: Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol 1995, 69:1851-1859.
143. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, Jay G: Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995, 9:41-47.
144. Pasquinelli C, Bhavani K, Chisari FV: Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice. Cancer Res 1992, 52:2823-2829.
145. Kekule AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R: The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990, 343:457-461.
146. Fu XX, Su CY, Lee Y, Hintz R, Biempica L, Snyder R, Rogler CE: Insulinlike growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers. J Virol 1988, 62:3422-3430.
147. Yoo YD, Ueda H, Park K, Flanders KC, Lee YI, Jay G, Kim SJ: Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest 1996, 97:388-395.
148. Bock CT, Tillmann HL, Manns MP, Trautwein C: The pre-S region determines the intracellular localization and appearance of hepatitis B virus. Hepatology 1999, 30:517-525.
149. Xu Z, Jensen G, Yen TS: Activation of hepatitis B virus S promoter by the viral large surface protein via induction of stress in the endoplasmic reticulum. J Virol 1997, 71:7387-7392.
150. Jakubczak JL, Chisari FV, Merlino G: Synergy between transforming growth factor alpha and hepatitis B virus surface antigen in hepatocellular proliferation and carcinogenesis. Cancer Res 1997, 57:3606-3611.
151. Yeh SH, Lin MW, Lu SF, Wu DC, Tsai SF, Tsai CY, Lai MY, Hsu HC, Chen DS, Chen PJ: Allelic loss of chromosome 4q21 approximately 23 associates with hepatitis B virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. Hepatology 2004, 40:847-854.
152. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K: The long-term pathological evolution of chronic hepatitis C. Hepatology 1996, 23:1334-1340.
153. Kew MC: Hepatitis C virus and hepatocellular carcinoma. FEMS Microbiol Rev 1994, 14:211-219.
154. Nardone G, Romano M, Calabro A, Pedone PV, de Sio I, Persico M, Budillon G, Bruni CB, Riccio A, Zarrilli R: Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology 1996, 23:1304-1312.
155. Tanaka S, Takenaka K, Matsumata T, Mori R, Sugimachi K: Hepatitis C virus replication is associated with expression of transforming growth factor-alpha and insulin-like growth factor-II in cirrhotic livers. Dig Dis Sci 1996, 41:208-215.
156. Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, Onishi E, Andoh T, Yoshida I, Okayama H: Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991, 65:1105-1113.
157. Borowski P, Oehlmann K, Heiland M, Laufs R: Nonstructural protein 3 of hepatitis C virus blocks the distribution of the free catalytic subunit of cyclic AMP-dependent protein kinase. J Virol 1997, 71:2838-2843.
158. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM: Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285:107-110.
159. Gale M Jr, Kwieciszewski B, Dossett M, Nakao H, Katze MG: Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 1999, 73:6506-6516.
160. Koromilas AE, Roy S, Barber GN, Katze MG, Sonenberg N: Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 1992, 257:1685-1689.
161. Shih CM, Lo SJ, Miyamura T, Chen SY, Lee YH: Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993, 67:5823-5832.
162. Kim DW, Suzuki R, Harada T, Saito I, Miyamura T: Trans-suppression of gene expression by hepatitis C viral core protein. Jpn J Med Sci Biol 1994, 47:211-220.
163. Ray RB, Steele R, Meyer K, Ray R: Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997, 272:10983-10986.
164. Ray RB, Steele R, Meyer K, Ray R: Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. Gene 1998, 208:331-336.
165. Ruster B, Zeuzem S, Roth WK: Hepatitis C virus sequences encoding truncated core proteins detected in a hepatocellular carcinoma. Biochem Biophys Res Commun 1996, 219:911-915.
166. Tai DI, Tsai SL, Chen YM, Chuang YL, Peng CY, Sheen IS, Yeh CT, Chang KS, Huang SN, Kuo GC, Liaw YF: Activation of nuclear factor kappa B in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 2000, 31:656-664.
167. Sung JL, Chen DS: Hepatitis B antigen and antibody in liver disease in Taiwan. Proceedings 5th Asian Pacific Congress of Gastroenterology: Singapore 1976:265-269.
168. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997, 336:1855-1859.
169. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993, 119:312-323.
170. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998, 339:1485-1492.
171. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998, 352:1426-1432.
172. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
173. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
174. Dianzani F, Antonelli G, Capobianchi MR: The biological basis for clinical use of interferon. J Hepatol 1990, 11(Suppl 1):5-10.
175. Iwase S, Furukawa Y, Kikuchi J, Nagai M, Terui Y, Nakamura M, Yamada H: Modulation of E2F activity is linked to interferon-induced growth suppression of hematopoietic cells. J Biol Chem 1997, 272:12406-12414.
176. Raveh T, Hovanessian AG, Meurs EF, Sonenberg N, Kimchi A: Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons. J Biol Chem 1996, 271:25479-25484.
177. Arany I, Rady P, Tyring SK: Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGF beta 1/IFN beta cytokine pathway. Antiviral Res 1994, 23:131-141.
178. Merle P, Chevallier M, Levy R, Maisonnas M, Terradillos O, Ahmed SNS, Trepo C, Buendia MA, Vitvitski-Trepo L: Preliminary results of interferon-alpha therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice. J Hepatol 2001, 34:562-569.
179. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995, 92:4562-4566.
180. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996, 334:1422-1427.
181. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999, 29:971-975.
182. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL: Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001, 34:139-145.
183. Oon CJ: Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992, 31(Suppl):137-142.
184. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A, Roda E: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996, 24:141-147.
185. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW: Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997, 26:1338-1342.
186. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, Koida I, Arase Y, Chayama K, Murashima N, Kumada H: Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998, 82:827-835.
187. International Interferon-alpha Hepatocellular Carcinoma Study Group: Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998, 351:1535-1539.
188. Benvegnù L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A: Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998, 83:901-909.
189. Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G, Fuschi P, Almasio PL, Craxi A: The long-term course of chronic hepatitis B. Hepatology 1999, 30:257-264.
190. Camma C, Giunta M, Andreone P, Craxi A: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001, 34:593-602.
191. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
192. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998, 27:1394-1402.
193. Camma C, Di Marco V, Lo Iacono O, Almasio P, Giunta M, Fuschi P, Vaccaro A, Fabiano C, Magrin S, Di Stefano R, Bonura C, Pagliaro L, Craxi A: Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998, 28:531-537.
194. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999, 131:174-181.
195. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T: Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C. Oncology 2001, 61:134-142.
196. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, Solinas A, Brouwer JT, Thomas H, Realdi G, Corrocher R, Schalm SW: Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997, 27:201-205.
197. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R: Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998, 27:1435-1440.
198. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998, 129:94-99.
199. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, Boucher E, Miguet JP, Parlier D, Lemonnier C, Opolon P: Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999, 29:1870-1875.
200. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, Nishioji K, Murakami Y, Kashima K: Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 1999, 30:653-659.
201. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995, 346:1051-1055.
202. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, Habu D, Tanaka T: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001, 357:196-197.
203. Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, Magalotti D, Cursaro C, Calabrese C, Arienti V, Rossi C, Di Febo G, Zoli M, Craxi A, Gasbarrini G, Bernardi M: Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001, 48:843-848.
204. Testino G, Ansaldi F, Andorno E, Ravetti GL, Ferro C, De Iaco F, Icardi G, Valente U: Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis. Hepatogastroenterology 2002, 49:1636-1638.
205. Tanaka K, Sata M, Uchimura Y, Suzuki H, Tanikawa K: Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma? Oncol Rep 1998, 5:205-208.
206. Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A, Michielsen PP, Bellobuono A, Chemello L, Pastore G, Chen DS, Brouwer JT: Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999, 117:408-413.
207. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673-1680.
208. Pagliaro L, Craxi A, Camma C, Tine F, Di Marco V, Lo Iacono O, Almasio P: Interferon-αα for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 1994, 19:820-828.
209. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000, 32:228-232.
210. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002, 89:418-422.
211. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, Liaw YF: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004, 100:376-382.